New Product

Mirisetron (WAY-100579, SEC-579) is an indole-based 5-HT3 receptor antagonist exhibiting cognitive-enhancing effects. It counteracts learning deficits associated with central cholinergic neuronal dysfunction and may be employed in studying neurological disorders such as Alzheimer's disease.

Imofinostat (MPT0E028) is a selective, orally available pan-HDAC inhibitor with IC₅₀ values of 53.0/106.2/29.5 nM against HDAC1/HDAC2/HDAC6 in HCT116 cells. In B-cell lymphoma, Imofinostat induces cell cycle arrest and apoptosis whilst inhibiting Akt phosphorylation, demonstrating anticancer activity across multiple tumour types.

TS-0022666 is a selective TUT4/7 inhibitor exhibiting antiproliferative and anti-leukaemic activity in vivo and in vitro. It enhances THP-1 cell sensitivity to BCL-2 inhibition, reduces uridylation, and may be used to study cancers with FOCAD deficiency.

Otaplimastat HCl is a matrix metalloproteinase (MMP) inhibitor that blocks NMDA receptor-mediated excitotoxicity competitively and exhibits antioxidant activity,In oxygen-glucose-deprived endothelial cells, otaplimastat suppressed the activity rather than protein expression of MMPs by restoring the level of tissue inhibitor of metalloproteinase (TIMP) suppressed in ischemia, and consequently reduced vascular permeation. serving as a tool for research into brain ischemic injury and neuroprotection.

GNE-0439 is a novel, Nav1.7-selective inhibitor with an IC50 of 0.34 uM that also inhibits Nav1.5 (IC50=38.3 uM) and mutant N1742K channels (IC50=0.37 uM), possessing a carboxylic acid group that binds outside the channel pore, distinguishing it from known selective VSD4 binders and making it a valuable tool for ion channel research.

NOD1/2 antagonist-1 is a dual inhibitor of nucleotide-binding oligomerization domain-like receptors NOD1 and NOD2, exhibiting IC50 values of 1.13 uM for NOD1 and 0.77 uM for NOD2, with an acceptable half-life of 67.6 minutes. NOD1/2 antagonist-1 enhances the antitumor efficacy of paclitaxel and serves as a potent experimental tool for investigating innate immune receptor-mediated signaling and cancer therapy modulation.

BBO-10203 is an orally active small molecule, also designated as Compound 758, that functions as a selective PI3Kα-Ras interaction disruptor by binding to the Ras-binding domain of PI3Kα. BBO-10203 effectively prevents Ras-PI3Kα complex formation, inhibits downstream Akt activation without altering basal PI3Kα kinase activity, thereby minimizing risks of hyperglycemia and hyperinsulinemia, and displays selective antitumor activity against KRAS-mutant malignancies, making it an important investigational candidate for targeted cancer therapeutics.

Methaphenilene hydrochloride is a histamine H1 receptor antagonist that functions as an analogue of the antihistaminic compound methapyrilene. Methaphenilene hydrochloride exhibits both antihistaminic and anticholinergic properties, making it an effective pharmacological agent for the study of allergic inflammation and autonomic nervous system regulation.

Zelpolib is a specific inhibitor of DNA polymerase δ (Pol δ), thereby inhibiting DNA replication and DNA double-strand break homologous recombination repair. It exhibits antiproliferative activity in triple-negative breast cancer cell lines, pancreatic cancer cell lines, and platinum-resistant pancreatic cancer cell lines.

Afurolol Hydrochloride (DL 071-IT) is a non-selective β-adrenergic receptor antagonist. DL 071 IT exhibits intrinsic sympathomimetic activity, reducing exercise heart rate, systolic blood pressure, and resting heart rate.

Ralimetinib is a selective inhibitor that blocks phosphorylation of MK2 at Thr334, without affecting the phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc. Ralimetinib functions as an ATP-competitive inhibitor of p38 MAPK α/β, demonstrating IC50 values of 5.3 and 3.2 nM, respectively, and is under investigation as an anti-inflammatory and anticancer therapeutic.

Lemuteporfin is a light-activated photosensitizing agent that is rapidly internalized by viable cells, localizing within the cytoplasm and associating with mitochondria. This localization is a key characteristic that confers strong cytotoxic potential upon light activation. Lemuteporfin has demonstrated the ability to reduce sebaceous gland volume in preclinical animal studies. It is currently under investigation in relation to benign prostatic hyperplasia and in topical form for the management of androgenetic alopecia.

BC-1293 is an inhibitor of the E3 ligase subunit FBXO24 that acts by disrupting the interaction between FBXO24 and aspartyl-tRNA synthetase (DARS2). BC-1293 treatment results in increased levels of DARS2, showing its capacity to stabilize this essential enzyme. Furthermore, BC-1293 elevates levels of cytokines including IL-1β, IL-9, MIP-2, and TNF-α in murine models, thereby demonstrating immunostimulatory activity with potential relevance to immune modulation research.

AGN 205327 is a potent synthetic agonist of retinoic acid receptors (RARs), with EC50 values of 3766 nM for RARα, 734 nM for RARβ, and 32 nM for RARγ, and AGN 205327 demonstrates no inhibitory activity against retinoid X receptors (RXRs), thereby exhibiting selective receptor subtype targeting that makes AGN 205327 an important tool for probing retinoid signaling pathways and investigating therapeutic applications of RAR activation.

Lanadelumab (SHP643) is a humanized IgG1 monoclonal antibody targeting plasma kallikrein (pKal) with a Ki value of 0.12 nM. Lanadelumab effectively inhibits both free pKal and its interaction with high molecular weight kininogen (HMWK)-bound pKal. Lanadelumab has demonstrated potential in hereditary angioedema research and represents a promising therapeutic antibody for studying kallikrein-kinin system regulation.

Tebideutorexant is a selective antagonist of the orexin-1 receptor and has demonstrated anti-panic effects in both rodent and human models of panic-anxiety. Tebideutorexant provides valuable insights into orexin signaling pathways in stress response and has potential utility as a tool compound for psychiatric and neurobehavioral disorder research.

FCE-27164 is a therapeutic agent that inhibits the binding of platelet-derived growth factor beta and interleukin-7 (IL-7) to their respective receptors, potentially modulating inflammatory and immune responses.

D-Isofloridoside, a polysaccharide precursor, exhibits free radical scavenging activity and inhibits both ROS expression and the enzymes MMP-2 and MMP-9.

CP-457920 is a selective α 5 GABAA receptor agonist for the treatment of dementia in Alzheimer's disease.

β-Naltrexamine dihydrochloride is an orally administered, irreversible opioid receptor antagonist. Its derivatives exhibit optimised subtype selectivity and can be used for pain research.

CBL 0100 free base is an HIV-1 transcription inhibitor that blocks HIV-1 replication and reactivation in vitro and in ex vivo models. It targets the chromatin-associated transcription (FACT) complex, reducing the occupancy of RNA Polymerase II and FACT in the HIV-1 promoter region, and can be used as a latency-reversing agent (LRA) in cART therapy.

Imelciment (REGN-9035) is a humanised monoclonal antibody targeting NPR1, which can be used for research into heart failure.

Sacituzumab tirumotecan (SKB264) is an antibody-drug conjugate (ADC) targeting TROP2 (trophoblast cell surface antigen 2), capable of releasing the active payload KL610023 within TROP2-positive tumour cells. an effective topoisomerase I inhibitor that induces DNA damage and leads to cell cycle arrest and apoptosis, for use in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).

Beauveriolide III, a cyclodepsipeptide found in Beauveria fungi, inhibits lipid droplet formation (at 3-10 μM) and cholesterol synthesis (IC50=0.41 μM). This compound also suppresses acyl-coenzyme A:cholesterol acyltransferase (ACAT) activity (IC50=5.5 μM) and reduces atherosclerotic lesion size in Ldlr-/- and ApoE-/- mouse models (25-50 mg/kg).

GSK-7227, a novel compound representing a novel class of peroxisome proliferator-activated receptor delta (PPARδ) partial agonists, demonstrates potent partial agonistic activity by upregulating the expression of PPARδ target genes, specifically carnitine palmitoyltransferase 1a (CPT1a) and pyruvate dehydrogenase kinase 4 (PDK4), in cultured skeletal muscle cells, indicating its potential role in modulating skeletal muscle metabolism and energy homeostasis.

B-TPMF is a highly efficient and selective KCa2.1 channel inhibitor with an IC50 of 31 nM, interacting with the serine residue at position 293 to inhibit KCa2.1.

Motugivatrep is a potent and selective TRPV1 antagonist that can be used to study TRPV1-related respiratory diseases.

PD-102807 is a selective and competitive M4 muscarinic receptor antagonist (IC50 = 90.7 nM), with IC50 values of 950–7412 nM for M1, M2, M3, and M5 receptors, and can be used for Parkinson's disease research, as well as to inhibit airway smooth muscle (ASM) contraction.

KLS-13019 is a highly effective and orally active GPR55 receptor antagonist, a cannabidiol (CBD)-derived neuroprotective agent that can reverse chemotherapy-induced peripheral neuropathy (CIPN) and is suitable for studying hepatic encephalopathy (HE).

LRH-1 Inhibitor-3 is an antagonist that inhibits LRH-1 transcriptional activity, reducing the expression of target genes associated with cell growth and proliferation, such as SHP (small heterodimer partner), cyclin E1 (CCNE1), and G0S2, and inhibiting the proliferation of human pancreatic, colon, and breast adenocarcinoma cells.

RLX (PD 139530) is a PI3K/Akt/FoxO3a signal inhibitor with anticancer activity against tumour cell lines such as colon cancer, inducing sub-G1 arrest and mitochondrial potential loss, thereby inhibiting tumour growth. RLX also exhibits antitussive and anti-asthmatic activity, reducing eosinophils and total lymphocytes in bronchoalveolar lavage (BAL) fluid, and exhibits toxicity toward A549 cells.

PF-184563 is an effective and selective non-peptide antagonist of the V1a receptor with oral activity, suitable for studying Raynaud's disease and dysmenorrhoea.

GNE-0723 is a selective positive allosteric modulator of the NMDA receptor, with an EC50 of 21 nM for GluN2A. It can cross the blood-brain barrier (BBB) and improve outcomes in Dravet syndrome (DS) and Alzheimer's disease (AD).

dWIZ-1 ((rac)-dWIZ-1) is a potent WIZ molecular gel degrader that recruits WIZ (ZF7) to the cereblon thereby inducing degradation and thus induction of haemoglobin fetalis (HbF) in erythroblasts, which can be used to study sickle cell disease (SCD).

VAV1 degrader-2 (Example 176) is a molecular gel degrader (DC50=4.41 nM) that targets VAV 1 for the study of inflammatory and autoimmune diseases.

DDD01035881 is a novel and highly potent anti-malarial drug that blocks parasite-to-mosquito transmission with nanomolar activity by targeting the Plasmodium vesicle membrane protein Pfs16 and blocking the formation of male gametes in the life cycle of the malaria parasite.

Anti-SEZ6 Antibody (SC17) is an IgG1 monoclonal antibody targeting SEZ6, which can be used for the synthesis of antibody-drug conjugates (ADCs), such as ABBV-011.

GNE-5729 is a positive allosteric modulator of NMDAR with the advantage of crossing the blood-brain barrier and being orally available, with EC50 values of 37 nM, 4.7 μM and 9.5 μM for GluN2A, GluN2C and GluN2D, respectively, and can be used for the study of neurological and psychiatric disorders.

NBD-PE is a lipid dye used primarily as a probe to study lipid organisation and dynamics within cell membranes and also to study membrane fusion by fluorescence resonance energy transfer (FRET), Ex=463 nm, Em=536 nm.

(R)-DOI hydrochloride is a potent 5-HT2A and 5-HT2C receptor agonist, orally active and capable of producing hallucinogenic effects.

PZL-A, an activator of mtDNA synthesis, restored the function and activity of the most common POLγ mutant variant and activated mtDNA synthesis in the cells of pediatric patients with fatal diseases, thereby enhancing the oxidative phosphorylation mechanism and the biogenesis of cellular respiration, and can be used to treat progressive diseases associated with mtDNA depletion.

ICSN3250 HCl is an mTOR inhibitor that specifically targets cancer cells, competing with and displacing phosphatidic acid in the FRB structural domain of mTOR, thereby preventing mTOR activation and leading to cytotoxicity.

MG-T-19, a TIM-3 inhibitor (KD=0.26 μM), significantly inhibited the interaction of TIM-3 with PtdSer, CEACAM1, and Gal-9, and increased the production of TNF-α and IFN-γ in PBMCs, which reactivated the tumor-attacking ability of T cells.

SIRT5 inhibitor 2 (compound 49) is a potent SIRT5 inhibitor with IC50=2.3 μM that has inhibitory activity through SIRT5-dependent deacetylation and can be used to study cancer and neurodegenerative diseases.

SSJ-183 is a low-toxicity and orally available and anti-malarial drug with an IC50 = 7.6 nM against P. falciparum and no lethality at doses up to 2000 mg/kg po.

Trimethylcolchicinic acid (N-Deacetylcolchiceine) is an orally available colchicine analog that binds to tubulin and inhibits its polymerization into microtubules, preventing cell division and having potential antitumor activity.

STX-107 is a potent and selective mGluR5 agonist for the study of Fragile X Syndrome.

IKs124 is a KCNE2/KCNQ1 potassium channel blocker with an IC50 = 8 nM, as well as an IC50 of 370 nM and 440 nM for KCNE1 and KCNE3, respectively, and can be used to study peptic ulcers.

ABBV-969 Payload (Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT) is a drug-linker conjugate employed in the synthesis of antibody-drug conjugates (ADCs). The ABBV-969 Payload contains a Topoisomerase I inhibitor molecule and a chemical linker, enabling coupling with anti-c-Met antibodies to generate ABBV-969 ADCs with targeted anticancer activity.

AZD0022 is a selective, reversible, and orally active KRAS G12D inhibitor exhibiting high affinity for both active (KRAS G12D-GTP) and inactive (KRAS G12D-GDP) proteins, whilst demonstrating selectivity for wild-type KRAS. AZD0022 exhibits tumour marker inhibition in PDAC and NSCLC models, making it suitable for investigating tumours such as advanced solid tumours, pancreatic cancer, and colorectal cancer.

BMS-986449 is an IKZF2 (Helios)/IKZF4 (Eos) degrader and CELMoD molecular glue. It redirects the interaction between the E3 ubiquitin ligase Cereblon and Helios/Eos in primary Treg cells, inducing their degradation, and may be utilised for anti-tumour immunotherapy.

The FAP-targeting peptide for FXX489 constitutes the peptide moiety of FXX489, suitable for biochemical assays and drug synthesis studies. FXX489 is a fibroblast activation protein (FAP)-targeting ligand employed in radioligand therapy (RLT) for multiple cancers.

RMC5127 is an orally available, mutation-selective RAS G12V inhibitor exhibiting central nervous system (CNS) and brain permeability. It suppresses the RAS pathway and induces apoptosis in KRAS G12V mutant cancer cells, demonstrating antitumour activity.

GSK4418959 (IDE275) is a non-covalent, reversible, selective, and orally active inhibitor of the Werner syndrome helicase (WRN helicase). GSK4418959 inhibits both ATPase and DNA unwinding activities of WRN helicase in an ATP-competitive manner. GSK4418959 is a valuable chemical tool for the study of microsatellite instability-high (MSI-H) cancers, where WRN helicase plays an essential role in maintaining genomic stability.

GDC-2992 is a selective and orally active androgen receptor (AR) degradator that degrades AR (DC50 = 2.7 nM) and inhibits proliferation (IC50 = 9.7 nM) in VCaP cells, making it suitable for studying castration-resistant prostate cancer (CRPC).

AMG410 is a non-covalent, dual-modality KRAS inhibitor effective against both GDP (OFF) and GTP (ON) binding, with Kd (GDP) of 1 nM and Kd (GTP) of 22 nM, capable of blocking KRAS independently of the cell cycle. AMG410 does not affect HRAS and NRAS2, and exhibits high potency against KRAS G12D, G12V, G12C, G13D, and other mutants, with an IC₅₀ of 1–4 nM. It induces tumour regression and reduces phosphorylated ERK levels in KRAS-mutant cancer models.

ABP-102 (CT P72) is a tetravalent IgG1-[L]-scFv bispecific t-cell adduct (BiTE) that acts as a CD3 modulator and selective HER2 modulator for the selective targeting of HER2 overexpressing tumors. ABP-102 showed cytotoxicity in HER2-overexpressing models of breast and gastric cancers, while significantly decreasing activity against HER2 low level cells, twice as effective as rununmotamab.

M0324 is a novel MUC-1 conditional CD40 agonist composed of an anti-MUC-1 IgG and two identical CD40-targeting camelid VHH domains, designed to selectively activate immune cells in the context of tumor cells with high MUC-1 expression.

RO7567132 (FAP-LTBR) is a novel bispecific antibody that binds and agonizes LTBR bivalently while binds and antagonizes FAP monovalently, thereby limiting the activation of LTBR to the tumor microenvironment, inducing the formation of local tertiary lymphoid structures (TLS), and reducing systemic toxicity. Its mouse alternative can inhibit breast cancer growth, and the effect is better when combined with atezolizumab. In the mouse colorectal cancer model, it can also enhance immune cell infiltration and TLS-like structure formation.

ACLY Inhibitor 7 is a highly potent and selective small molecule inhibitor that exhibits exceptional inhibitory activity against human ATP citrate lyase (hACLY). ACLY Inhibitor 7 demonstrates an IC50 value of less than 1 nM as measured by the ADP-Glo assay, indicating its potential for metabolic disease and oncology research.

MC-Val-Cit-PAB-Amide-TLR7 agonist 4 TFA is the trifluoroacetate form of MC-Val-Cit-PAB-Amide-TLR7 agonist 4. MC-Val-Cit-PAB-Amide-TLR7 agonist 4 is a HER2-TLR7 and HER2- TLR8 immune agonist complexes with potential antitumor activity by activating the TLR7 and TLR8 signaling pathways and enhancing immune responses.

Bavtavirine is a potent non-nucleoside reverse transcriptase inhibitor (NNRTIs) that inhibits HIV replication by inhibiting HIV-1 reverse transcriptase activity and preventing the transcription of viral RNA into DNA for use in Highly Active Antiretroviral Therapy (HAART) programs and HIV disease studies

Vaniprevir is a non-covalent competitive HCV NS3/4A protease inhibitor, an antiviral drug that acts directly on the hepatitis C virus. Vaniprevir blocks the viral replication process by inhibiting the activity of HCV NS3/4A protease.

GW 583340 dihydrochloride is a potent and orally available dual EGFR/ErbB2 (epidermal growth factor receptor/tyrosine kinase) inhibitor and is capable of reversing ABCG2- and ABCB1-mediated resistance.GW 583340 dihydrochloride selectively inhibits the growth of human tumor cells overexpressing EGFR and ErbB2, selectively inhibits the growth of human tumor cells overexpressing EGFR and ErbB2, and inhibits 80% of tumor growth in a mouse xenograft model, with potential anticancer activity.

DX3-235 is an oxidative phosphorylation (OXPHOS) inhibitor with nanomolar-level inhibitory effects on mitochondrial complex I function in galactose-containing media, resulting in reduced ATP production, leading to impaired cellular energy metabolism and cancer cytotoxicity.

SU 10603 is a specific inhibitor of 17α-hydroxylase (also known as CYP17A1 and P450c17) used to study steroid hormone synthesis.

CHDI 00484077 is a highly selective, central nervous system (CNS) permeable Class IIa HDAC inhibitor with inhibitory effects on HDAC4, HDAC5, HDAC7, and HDAC9, which improves neuronal function, and can be used to study Huntington's disease.

DX3-234 is a potent oxidative phosphorylation (OXPHOS) inhibitor that acts by inhibiting complex I in the mitochondrial electron transport chain (ETC), leading to intracellular ATP depletion and cell death, and can be used for the treatment of specific cancers dependent on aerobic metabolism, such as pancreatic cancer.

Rubone (2'-Hydroxy-2,4,4',5,6'-pentamethoxychalcone), a natural product and a modulator of miR-34a (microRNA-34), upregulates miR-34a expression in a p53-dependent manner, which in turn downregulates the expression of downstream targets Bcl-2, cyclin-D1, CDK6, SIRT1, and FOXP1, thereby inhibiting tumor growth and reversal of hepatocellular carcinoma (HCC) and chemoresistance in prostate cancer.

APJ receptor agonist 8 is a small molecule agonist of the APJ receptor, enhancing load-independent cardiac contractility in isolated perfused rat hearts. It mimics the action of the endogenous ligand Apelin and has an EC50 of 21.5 µM.

Lodelaben (Declaben, SC-39026) is a reversible, non-competitive inhibitor of human neutrophil elastase (HNE), characterized by specificity and potency (IC50=0.5 μM, Ki=1.5 μM).

Solenopsin HCl is an alkaloid extracted from fire ants, inhibiting phosphoinositide 3-kinase signaling and angiogenesis in a dose-dependent manner, affecting cardiovascular function, and used in cardiovascular disease research.

KRH102140 is a PHD2 activator that reduces angiogenesis by inhibiting HIF-1alpha, used in cardiovascular disease research.

Spirorenone (INN) is a novel aldosterone antagonist with anti-salt corticosteroid activity, used in metabolic disease research.

BRD4884 is a highly selective and efficient HDAC1 and HDAC2 inhibitor that also inhibits HDAC3, used in research on neurological disorders.

QPX7728 disodium (Xeruborbactam disodium) is a cyclic boronate inhibitor of many serine and metal-β-lactamases with antibacterial activity, used in research on bacterial infections.

iHCK-37 (ASN05260065) is a selective Hck inhibitor with antitumor activity, blocking HIV-1 viral replication. iHCK-37 reduces PI3K/AKT and MAPK/ERK pathway activation after erythropoietin induction in high Hck-expressing cells, useful in chronic myelogenous leukemia (CML) research.

DT204 is an SCFSkp2 inhibitor that reduces the binding of Skp2 to Cullin-1 and Commd1. It can be used to study multiple myeloma.

Factor B-IN-5 is a complement factor B inhibitor, which can be used to study immune-related diseases.

PF-06647263 (anti-EFNA4-ADC) is an ADC compound targeting EFNA4, with anti-tumor activity, composed of an anti-EFNA4 antibody conjugated with calicheamicin, inducing significant tumor regression in TNBC xenografts.

DEDN6526A (RG-7636) is a humanized ADC compound targeting endothelin B receptor (ETBR), which can be used to study melanoma.

RMM-46 is a reversible covalent inhibitor with high ligand efficiency and selectivity for MSK/RSK family kinases.

BMH-7 HCl is a p53 activator, showing anticancer activity through the activation of the p53 pathway.

RIPK2-IN-3 (FCG806791773) is a receptor-interacting serine/threonine protein kinase 2 (RIPK2) inhibitor with anti-inflammatory and anti-tumor activity. It can be used for research on immune diseases and cancer.

MK-3984 is a selective androgen receptor modulator, used in the study of conditions caused by androgen deficiency.

BI-135585 is an orally active, selective and potent inhibitor of human 11β-hydroxysteroid dehydrogenase-1 (HSD1) for the study of type 2 diabetes.

Suntinorexton (TAK 861) is an orexin type 2 receptor (OX2R) agonist for the study of neurological disorders.

Apelin agonist 1 is an orally available APJ receptor agonist with an EC50 value of 3.2 nM. Apelin agonist 1 is used in the study of cardiovascular disease.

HTT-D3 is an orally active, highly efficient Huntington splicing modulator. It induces HTT mRNA degradation, reduces HTT protein levels, and inhibits P-glycoprotein (P-gp) efflux. This compound can be used in Huntington's disease research.

Pulrodemstat (CC-90011) is an orally active, selective, and highly efficient lysine-specific demethylase-1 (LSD1) inhibitor with anticancer activity. It inhibits HNSCC cell proliferation and migration by triggering apoptosis and inhibiting head and neck squamous cell carcinoma growth.

JNJ-26489112 is a CNS-active agent and inhibitor of voltage-gated Na+ channels and N-type Ca2+ channels with broad-spectrum anticonvulsant activity in rodents and can be used to study neurological disorders.

CEP-9722 is an orally active, selective and potent inhibitor of poly (ADP-ribose) polymerase-1 PARP-1 and poly (ADP-ribose) polymerase-12 PARP-2, with anticancer activity, and can be used for the study of ovarian cancer.

KU-177 is a Hsp90 ATPase homolog 1 (Aha1) inhibitor. By disrupting the interaction between Hsp90 and Aha1, it prevents the proliferation of primary MM and relapsed MM patient samples. It eliminates the proliferation and PI resistance induced by AHSA1 elevation.

PAOPA is a novel dopamine D2 receptor modulator and L-proline-L-leucine-glycine amide (PLG) peptide mimetic that prevents and reverses behavioral and biochemical abnormalities in preclinical animal models of schizophrenia sensitized to amphetamine. PAOPA has been used in the study of schizophrenia and extrapyramidal dysfunction.

Cianopramine (Ro 112465) is a selective 5-hydroxytryptamine uptake inhibitor and a tricyclic antidepressant used in the study of neurological disorders.

Leritrelvir (RAY1216) is an orally active and highly potent protease inhibitor with antiviral activity that blocks cleavage of viral precursor proteins and inhibits viral replication in SARS-CoV-2.

Valomaciclovir stearate (A-174606. 0) is a nucleoside analog with antiviral activity against varicella-zoster virus (VZV), and has been used in the study of VZV infections.

Izeltabart Tapatansine (IMGC-936) is a CHO-expressing humanized next-generation medetonin-based ADC compound targeting ADAM9-expressing tumors, and exhibits cytotoxicity against ADAM9-positive human tumor cell lines for cancer research.

BI-4732 is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with high blood-brain barrier permeability, antitumor activity, inhibition of EGFR activation, and inhibition of T790M mutations.

5-OP-RU is a MAIT-activating ligand, the major antigen of MAIT cells, a mucosal adjuvant, induces efficient enrichment of mucosal-associated invariant T cells, and can be used to study Mycobacterium tuberculosis infections.